# Contents
Allianz Biotechnologie
Fund Assets in %
|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  | 2.4  2.3 |

100
80
60
40
20
0
97.6 97.7
USD	Cash reserves, other assets
| Development of net assets and | unit value in a 3-year comparison |  |
| --- | --- | --- |
|  |  | 30/06/2022 | 31/12/2021 | 31/12/2020 | 31/12/2019 |
| Net assets in EUR m |  |  |  |  |  |
| - Unit class A (EUR) | WKN: 848 186/ISIN: DE0008481862 | 273.3 | 305.7 | 267.9 | 296.0 |
| - Unit class R (EUR) | WKN: A2A MPU/ISIN: DE000A2AMPU5 | 1.2 | 1.5 | 419,495.00  1) | 77,027.55  1) |
| Unit value in EUR |  |  |  |  |  |
| - Unit class A (EUR) | WKN: 848 186/ISIN: DE0008481862 | 193.29 | 222.48 | 203.12 | 174.90 |
| - Unit class R (EUR) | WKN: A2A MPU/ISIN: DE000A2AMPU5 | 142.05 | 162.79 | 147.35 | 125.76 |

1) 
Not shown in EUR million due to the fund’s low volume.
| Asset overview at 30/06/2022 |  |
| --- | --- |
| Breakdown by asset category – country | Market value in EUR | % of net assets  *) |  | Breakdown by asset category – currency | Market value in EUR | % of net assets  *) |
| I. Assets |  |  |  | I. Assets |  |  |
| 1. Equities | 268,253,099.61 | 97.72 |  | 1. Equities | 268,253,099.61 | 97.72 |
| Germany | 2,795,834.39 | 1.02 |  | USD | 268,253,099.61 | 97.72 |
| France | 3,435,449.41 | 1.25 |  | 2. Bank deposits, money market | 5,946,676.58 | 2.16 |
| The Netherlands | 6,923,425.61 | 2.52 |  | instruments, money market funds and |  |  |
| Ireland | 13,100,537.00 | 4.77 |  | money market-related funds |  |  |
| Denmark | 1,398,210.80 | 0.51 |  | 3. Other assets | 773,899.84 | 0.28 |

*) 
Minor rounding differences may be the result of percentage rounding during the calculation.
II. Liabilities	-442,217.33	-0.16
| Switzerland | 1,808,199.69 | 0.66 |
| --- | --- | --- |
| UK | 24,943,466.27 | 9.09 |
| USA | 208,542,113.72 | 75.96 |
| Canada | 2,030,123.49 | 0.74 |
| British Virgin Islands | 3,275,739.23 | 1.20 |
| 2. Bank deposits, money market instruments, money market funds and | 5,946,676.58 | 2.16 |
| money market-related funds |  |  |
| 3. Other assets | 773,899.84 | 0.28 |
| II. Liabilities | -442,217.33 | -0.16 |
| III. Fund assets | 274,531,458.70 | 100.00 |

III. Fund assets	274,531,458.70	100.00

#### Investment portfolio at 30/06/2022
ISIN	Securities	Market	Shares/	Balance   Purchases Redemptions	Price	Market value	% of net
Units/	30/06/2022	EUR	assets
Currency	in the period under review
| Exchange-traded | securities |  |  |  |  |  | 268,253,099.61 | 97.72 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equities |  |  |  |  |  |  | 268,253,099.61 | 97.72 |
| Biotechnology |  |  |  |  |  |  | 211,515,916.10 | 77.05 |
| US0042251084 | Acadia Pharmaceuticals Inc. Reg.Shares | Shs | 48,205 | 18,805 | 0 USD | 14.220 | 656,208.21 | 0.24 |
| CH0499880968 | ADC Therapeutics S.A. Namens-Aktien Cl.C | Shs | 61,760 | 12,330 | 0 USD | 7.790 | 460,569.02 | 0.17 |
| US0070021086 | Adicet Bio Inc. Reg.Shares | Shs | 113,185 | 74,305 | 0 USD | 14.580 | 1,579,779.15 | 0.58 |
| US00847X1046 | Agios Pharmaceuticals Inc. Reg.Shares | Shs | 62,105 | 19,605 | 0 USD | 22.380 | 1,330,566.63 | 0.48 |
| US0197701065 | Allogene Therapeutics Inc. Reg.Shares | Shs | 45,285 | 0 | 0 USD | 11.680 | 506,345.78 | 0.18 |
| US02043Q1076 | Alnylam Pharmaceuticals Inc Reg.Shares | Shs | 30,100 | 0 | 7,015 USD | 145.430 | 4,190,544.71 | 1.53 |
| US0231112063 | Amarin Corp. PLC Reg.Shs (Sp.ADRs) | Shs | 8 | 0 | 0 USD | 1.820 | 13.94 | 0.00 |
| US0311621009 | Amgen Inc. Reg.Shares | Shs | 99,210 | 38,895 | 27,250 USD | 245.430 | 23,309,506.32 | 8.50 |
| US03753U1060 | Apellis Pharmaceuticals Inc. Reg.Shares | Shs | 46,640 | 34,810 | 0 USD | 45.190 | 2,017,673.37 | 0.73 |
| US04016X1019 | argenx SE Reg.Shares (Sp.ADRs) | Shs | 18,670 | 8,175 | 3,835 USD | 373.580 | 6,676,946.77 | 2.43 |
| US04351P1012 | Ascendis Pharma A/S Nav.-Akt. (Spons.ADRs) | Shs | 15,505 | 0 | 20,720 USD | 94.200 | 1,398,210.80 | 0.51 |
| US05153U1079 | Aura Biosciences Inc. Reg.Shares | Shs | 61,575 | 6,430 | 0 USD | 12.570 | 740,951.32 | 0.27 |
| US07373V1052 | Beam Therapeutics Inc Reg.Shares | Shs | 7,280 | 0 | 4,985 USD | 40.420 | 281,694.05 | 0.10 |
| US0887861088 | Bicycle Therapeutics Ltd. Reg.Shs (Spons.ADRs) | Shs | 67,505 | 67,505 | 0 USD | 17.160 | 1,108,927.63 | 0.40 |
| US09058V1035 | BioCryst Pharmaceuticals Inc. Reg.Shares | Shs | 297,865 | 175,525 | 36,065 USD | 10.810 | 3,082,443.66 | 1.12 |
| US09062X1037 | Biogen Inc. Reg.Shares | Shs | 24,400 | 0 | 14,980 USD | 205.230 | 4,793,808.16 | 1.75 |
| VGG111961055 | Biohaven Pharmac.Hldg Co.Ltd. Reg.Shares | Shs | 13,705 | 6,280 | 0 USD | 145.650 | 1,910,906.81 | 0.70 |
| US09061G1013 | Biomarin Pharmaceutical Inc. Reg.Shares | Shs | 50,320 | 0 | 0 USD | 83.920 | 4,042,556.39 | 1.47 |
| US09075V1026 | BioNTech SE Nam.-Akt. (sp.ADRs) | Shs | 20,570 | 16,050 | 23,990 USD | 141.980 | 2,795,834.39 | 1.02 |
| US09627Y1091 | Blueprint Medicines Corp. Reg.Shares | Shs | 17,925 | 0 | 22,875 USD | 52.210 | 895,906.81 | 0.33 |
| US15678U1280 | Cerevel Therapeutics Hld. Inc. Reg.Shares | Shs | 22,620 | 2,360 | 0 USD | 27.000 | 584,663.99 | 0.21 |
| US16383L1061 | ChemoCentryx Inc. Reg.Shares | Shs | 72,225 | 19,800 | 0 USD | 25.490 | 1,762,411.69 | 0.64 |
| CH0334081137 | CRISPR Therapeutics AG Nam.-Aktien | Shs | 22,345 | 0 | 10,130 USD | 63.000 | 1,347,630.67 | 0.49 |
| US23282W6057 | Cytokinetics Inc. Reg.Shares | Shs | 89,910 | 90,850 | 68,235 USD | 48.740 | 4,195,111.43 | 1.53 |
| US23954D1090 | Day One Biopharmaceuticals Inc Reg.Shares | Shs | 17,770 | 17,770 | 0 USD | 17.550 | 298,548.25 | 0.11 |
| US24823R1059 | Denali Therapeutics Inc. Reg.Shares | Shs | 14,820 | 0 | 15,125 USD | 28.980 | 411,146.47 | 0.15 |
| US30161Q1040 | Exelixis Inc. Reg.Shares | Shs | 30,420 | 52,625 | 22,205 USD | 20.790 | 605,429.64 | 0.22 |
| US31189P1021 | Fate Therapeutics Inc. Reg.Shares | Shs | 15,825 | 0 | 21,065 USD | 24.880 | 376,915.57 | 0.14 |
| US3755581036 | Gilead Sciences Inc. Reg.Shares | Shs | 316,835 | 16,520 | 56,415 USD | 62.480 | 18,950,651.73 | 6.90 |
| US40637H1095 | Halozyme Therapeutics Inc. Reg.Shares | Shs | 34,935 | 0 | 0 USD | 45.280 | 1,514,318.21 | 0.55 |
| IE00BQPVQZ61 | Horizon Therapeutics PLC Reg.Shares | Shs | 149,800 | 6,975 | 51,010 USD | 82.500 | 11,830,844.34 | 4.31 |
| US45253H1014 | ImmunoGen Inc. Reg.Shares | Shs | 376,220 | 364,705 | 178,080 USD | 4.360 | 1,570,284.51 | 0.57 |
| US45337C1027 | Incyte Corp. Reg.Shares | Shs | 30,635 | 0 | 18,270 USD | 75.890 | 2,225,627.18 | 0.81 |
| US4576693075 | Insmed Inc. Reg.Shares | Shs | 186,020 | 99,085 | 0 USD | 20.070 | 3,574,020.10 | 1.30 |
| US45826J1051 | Intellia Therapeutics Inc. Reg.Shares | Shs | 38,410 | 6,765 | 0 USD | 52.430 | 1,927,854.01 | 0.70 |
| US4622221004 | Ionis Pharmaceuticals Inc. Reg.Shares | Shs | 9,830 | 0 | 58,200 USD | 37.560 | 353,450.89 | 0.13 |
| US4622601007 | Iovance Biotherapeutics Inc. Reg.Shares | Shs | 79,880 | 35,680 | 0 USD | 10.890 | 832,752.44 | 0.30 |
| US46583P1021 | IVERIC Bio Inc. Reg.Shares | Shs | 247,655 | 133,445 | 0 USD | 9.680 | 2,294,945.82 | 0.84 |
| US48576A1007 | Karuna Therapeutics Inc Reg.Shares | Shs | 8,830 | 0 | 6,600 USD | 124.980 | 1,056,455.49 | 0.38 |
| US48576U1060 | Karyopharm Therapeutics Inc. Reg.Shares | Shs | 145,925 | 15,240 | 20,280 USD | 4.510 | 630,022.74 | 0.23 |
| US4923271013 | Keros Therapeutics Inc. Reg.Shares | Shs | 61,180 | 32,965 | 0 USD | 27.180 | 1,591,874.78 | 0.58 |
| US5011471027 | Krystal Biotech Inc. Reg.Shares | Shs | 42,875 | 23,825 | 0 USD | 64.660 | 2,653,932.13 | 0.97 |
| US5015751044 | Kymera Therapeutics Inc. Reg.Shares | Shs | 37,930 | 37,930 | 0 USD | 20.290 | 736,741.05 | 0.27 |
| US5588681057 | Madrigal Pharmaceuticals Inc. Reg.Shares | Shs | 4,950 | 0 | 0 USD | 71.940 | 340,898.91 | 0.12 |
| US59045L1061 | Mersana Therapeutics Inc. Reg.Shares | Shs | 191,525 | 20,005 | 0 USD | 4.450 | 815,897.23 | 0.30 |
| US60468T1051 | Mirati Therapeutics Inc. Reg.Shares | Shs | 31,270 | 21,515 | 8,625 USD | 67.240 | 2,012,822.90 | 0.73 |
| US60770K1079 | Moderna Inc. Reg.Shares | Shs | 117,250 | 76,055 | 38,530 USD | 142.810 | 16,029,554.37 | 5.84 |
| US61225M1027 | Monte Rosa Therapeutics Inc. Reg.Shares | Shs | 82,145 | 82,145 | 0 USD | 9.790 | 769,863.63 | 0.28 |
| US61775R1059 | Morphic Holding Inc. Reg.Shares | Shs | 48,625 | 31,370 | 0 USD | 21.170 | 985,440.60 | 0.36 |
| US6323071042 | Natera Inc. Reg.Shares | Shs | 18,700 | 18,700 | 61,510 USD | 36.870 | 660,031.59 | 0.24 |
| US64125C1099 | Neurocrine Biosciences Inc. Reg.Shares | Shs | 58,165 | 48,785 | 32,605 USD | 98.460 | 5,482,410.40 | 2.00 |
| US6700024010 | Novavax Inc. Reg.Shares | Shs | 23,030 | 29,975 | 22,455 USD | 51.850 | 1,143,122.25 | 0.42 |
| US74349U1088 | Prometheus Biosciences Inc. Reg.Shares | Shs | 51,533 | 40,463 | 0 USD | 27.820 | 1,372,437.35 | 0.50 |
| US74366E1029 | Protagonist Therapeutics Inc. Reg.Shares | Shs | 123,120 | 75,100 | 19,825 USD | 8.070 | 951,156.81 | 0.35 |
| IE00B91XRN20 | Prothena Corp. PLC Reg.Shares | Shs | 13,895 | 0 | 0 USD | 26.810 | 356,619.71 | 0.13 |
| US69366J2006 | PTC Therapeutics Inc. Reg.Shares | Shs | 12,095 | 0 | 46,980 USD | 40.400 | 467,775.22 | 0.17 |
| US75886F1075 | Regeneron Pharmaceuticals Inc. Reg.Shares | Shs | 19,950 | 2,220 | 820 USD | 597.620 | 11,413,477.89 | 4.16 |
| US77313F1066 | Rocket Pharmaceuticals Inc. Reg.Shares | Shs | 20,470 | 0 | 0 USD | 13.030 | 255,336.11 | 0.09 |
| US8036071004 | Sarepta Therapeutics Inc. Reg.Shares | Shs | 6,015 | 0 | 0 USD | 77.070 | 443,783.31 | 0.16 |
| US81181C1045 | Seagen Inc. Reg.Shares | Shs | 55,400 | 11,395 | 18,500 USD | 179.060 | 9,496,385.22 | 3.46 |
| US85205L1070 | SpringWorks Therapeutics Inc. Reg.Shares | Shs | 94,425 | 81,065 | 0 USD | 25.500 | 2,305,033.03 | 0.84 |
| US87164F1057 | Syndax Pharmaceuticals Inc. Reg.Shares | Shs | 87,555 | 26,125 | 0 USD | 19.080 | 1,599,224.01 | 0.58 |
| US89422G1076 | Travere Therapeutics Inc. Reg.Shares | Shs | 89,525 | 38,605 | 0 USD | 24.680 | 2,115,141.68 | 0.77 |

Explanations can be found in the footnotes below the table.

#### Investment portfolio at 30/06/2022
ISIN	Securities	Market	Shares/	Balance   Purchases Redemptions	Price	Market value	% of net
Units/	30/06/2022	EUR	assets
Currency	in the period under review
| US90041T1088 | Turning Point Therap. Inc. Reg.Shares | Shs | 13,820 | 0 | 1,603 USD | 75.300 | 996,214.82 | 0.36 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| US90400D1081 | Ultragenyx Pharmaceutical Inc. Reg.Shares | Shs | 21,095 | 10,730 | 8,565 USD | 60.240 | 1,216,506.61 | 0.44 |
| NL0010696654 | uniQure N.V. Aandelen op naam | Shs | 13,940 | 13,940 | 0 USD | 18.470 | 246,478.84 | 0.09 |
| US91307C1027 | United Therapeutics Corp.(Del.) Reg.Shares | Shs | 18,975 | 7,345 | 12,250 USD | 238.290 | 4,328,501.58 | 1.58 |
| US92532F1003 | Vertex Pharmaceuticals Inc. Reg.Shares | Shs | 75,000 | 12,895 | 6,585 USD | 280.350 | 20,128,518.09 | 7.34 |
| CA98420N1050 | Xenon Pharmaceuticals Inc. Reg.Shares | Shs | 68,630 | 29,145 | 20,720 USD | 30.900 | 2,030,123.49 | 0.74 |
| US9842411095 | Y-Mabs Therapeutics Inc. Reg.Shares | Shs | 32,085 | 3,350 | 0 USD | 14.590 | 448,133.40 | 0.16 |
| Biosciences: materials and services |  |  |  |  |  | 7,229,686.73 | 2.64 |
| US23285D1090	Cytek Biosciences Inc. Reg.Shares | Shs | 30,415 | 30,415 | 0 USD | 10.870 | 316,495.36 | 0.12 |
| US4523271090	Illumina Inc. Reg.Shares | Shs | 15,395 | 10,665 | 25,980 USD | 186.430 | 2,747,549.16 | 1.00 |
| US46266C1053	IQVIA Holdings Inc. Reg.Shares | Shs | 8,600 | 8,600 | 0 USD | 214.110 | 1,762,728.32 | 0.64 |
| US56600D1072	Maravai LifeSciences Hldgs Inc Reg.Shares Cl.A | Shs | 40,155 | 40,155 | 20,375 USD | 27.810 | 1,069,031.73 | 0.39 |
| US58506Q1094	Medpace Holdings Inc. Reg.Shares | Shs | 2,060 | 0 | 16,045 USD | 149.980 | 295,767.57 | 0.11 |
| US87166B1026	Syneos Health Inc. Reg.Shares A | Shs | 15,030 | 23,850 | 58,885 USD | 72.150 | 1,038,114.59 | 0.38 |
| Healthcare: equipment and products |  |  |  |  |  | 12,415,136.90 | 4.51 |
| US05465P1012	Axonics Inc. Reg.Shares | Shs | 15,325 | 61,385 | 46,060 USD | 57.680 | 846,205.25 | 0.31 |
| US2521311074	DexCom Inc. Reg.Shares | Shs | 27,860 | 27,860 | 0 USD | 75.450 | 2,012,288.91 | 0.73 |
| VGG312491084	Establishment Labs Holdings In Reg.Shares | Shs | 25,265 | 13,485 | 12,265 USD | 56.430 | 1,364,832.42 | 0.50 |
| US45168D1046	IDEXX Laboratories Inc. Reg.Shares | Shs | 2,110 | 2,110 | 1,685 USD | 358.220 | 723,572.85 | 0.26 |
| JE00BYSS4X48	Novocure Ltd. Reg.Shares | Shs | 40,500 | 14,880 | 9,520 USD | 72.400 | 2,807,007.47 | 1.02 |
| US70975L1070	Penumbra Inc. Reg.Shares | Shs | 5,450 | 5,450 | 0 USD | 130.250 | 679,554.37 | 0.25 |
| JE00BLG2ZQ72	Quotient Ltd. Reg.Shares | Shs | 113,495 | 0 | 0 USD | 0.248 | 26,890.69 | 0.01 |
| US82489T1043	Shockwave Medical Inc. Reg.Shares | Shs | 7,150 | 7,150 | 0 USD | 194.370 | 1,330,409.25 | 0.48 |
| US82710M1009	Silk Road Medical Inc. Reg.Shares | Shs | 30,145 | 30,145 | 0 USD | 37.500 | 1,082,172.60 | 0.39 |
| US8753722037	Tandem Diabetes Care Inc. Reg.Shares New | Shs | 26,765 | 38,460 | 11,695 USD | 60.190 | 1,542,203.09 | 0.56 |
| Healthcare: technology |  |  |  |  |  | 810,772.45 | 0.30 |
| US4577301090	Inspire Medical Systems Inc. Reg.Shares | Shs | 4,510 | 4,510 | 0 USD | 187.790 | 810,772.45 | 0.30 |
| Pharmaceuticals |  |  |  |  |  | 36,281,587.43 | 13.22 |
| US00461U1051	Aclaris Therapeutics Inc. Reg.Shares | Shs | 83,930 | 33,890 | 0 USD | 14.360 | 1,153,776.37 | 0.42 |
| US00771V1089	Aerie Pharmaceuticals Inc. Reg.Shares | Shs | 145,275 | 36,450 | 0 USD | 7.800 | 1,084,764.50 | 0.40 |
| US04335A1051	Arvinas Inc. Reg.Shares | Shs | 43,630 | 18,070 | 0 USD | 43.640 | 1,822,719.89 | 0.66 |
| US0463531089	Astrazeneca PLC Reg.Shares (Spons.ADRs) | Shs | 327,324 | 96,775 | 65,595 USD | 67.020 | 21,000,626.54 | 7.66 |
| US05464T1043	Axsome Therapeutics Inc. Reg.Shares | Shs | 5,960 | 5,960 | 0 USD | 36.490 | 208,194.91 | 0.08 |
| US46116X1019	Intra-Cellular Therapies Inc. Reg.Shares | Shs | 12,450 | 0 | 0 USD | 58.310 | 694,964.10 | 0.25 |
| IE00B4Q5ZN47	Jazz Pharmaceuticals PLC Reg.Shares | Shs | 6,100 | 6,100 | 0 USD | 156.360 | 913,072.95 | 0.33 |
| US7170811035	Pfizer Inc. Reg.Shares | Shs | 55,775 | 170,735 | 178,185 USD | 50.940 | 2,719,872.20 | 0.99 |
| US75615P1030	Reata Pharmaceuticals Inc. Reg.Shares | Shs | 9,030 | 0 | 0 USD | 32.050 | 277,054.85 | 0.10 |
| US80105N1054	Sanofi S.A. Act.Nom. (Sp. ADRs) | Shs | 68,135 | 68,135 | 0 USD | 52.670 | 3,435,449.41 | 1.25 |
| US98978V1035	Zoetis Inc. Reg.Shares Cl.A | Shs | 17,845 | 17,845 | 0 USD | 173.920 | 2,971,091.71 | 1.08 |
| Unlisted securities |  |  |  |  |  | 0.00 | 0.00 |
| Other securities |  |  |  |  |  | 0.00 | 0.00 |
| US284CVR0169	Elanco Animal Health Inc. |  |  |  |  |  |  |  |
| Anrechte (CVR Rights) | Shs | 64,110 | 0 | 0 USD | 0.000 | 0.00 | 0.00 |
| Total securities |  |  |  | EUR |  | 268,253,099.61 | 97.72 |
| Bank deposits, money market instruments, money market funds and money market-related funds |  |  |  |  |
| Bank deposits |  |  |  |  |
| EUR deposits with custodial office |  |  |  |  |
| State Street Bank International GmbH	EUR	5,775,570.94 | % | 100.000 | 5,775,570.94 | 2.10 |
| Deposits in non EU/EEA currencies |
| State Street Bank International GmbH | USD | 178,736.95 | % | 100.000 | 171,105.64 | 0.06 |

| Total bank deposits | EUR | 5,946,676.58 | 2.16 |
| --- | --- | --- | --- |
| Total of bank deposits, money market instruments, money market funds and money market-related funds  30) | EUR | 5,946,676.58 | 2.16 |
| Other assets |  |  |  |  |  |  |
|  | Accrued dividends | EUR | 51,421.05 |  | 51,421.05 | 0.02 |
|  | Receivables from unit transactions | EUR | 90,429.80 |  | 90,429.80 | 0.03 |
|  | Receivables from securities transactions | EUR | 632,048.99 |  | 632,048.99 | 0.23 |
| Total other assets |  |  |  | EUR | 773,899.84 | 0.28 |
| Other payables |  |  |  |  |  |  |
|  | Liabilities from unit transactions | EUR | -5,635.98 |  | -5,635.98 | 0.00 |
|  | Accruals | EUR | -436,581.35 |  | -436,581.35 | -0.16 |
| Total other payables |  |  |  | EUR | -442,217.33 | -0.16 |
| Fund assets |  |  |  | EUR | 274,531,458.70 | 100.00 |
|  | Total units in circulation of all unit classes |  |  | SHS | 1,422,535 |  |

30) 
Cash initial margins may be included in bank deposits.
Allianz Biotechnologie A (EUR)
| ISIN | DE0008481862 |
| --- | --- |
| Fund assets | 273,319,155.72 |
| Units in circulation | 1,414,000.732 |
| Unit value | 193.29 |

Allianz Biotechnologie R (EUR)
| ISIN | DE000A2AMPU5 |
| --- | --- |
| Fund assets | 1,212,302.98 |
| Units in circulation | 8,534.382 |
| Unit value | 142.05 |


### Securities prices/market rates
Fund assets were valued on the basis of the following prices/market rates:
North and South American equities: prices as at 29/06/2022 or last known All other assets: prices/market rates as at 30/06/2022 or last known

### Additional information on valuations
The valuation is carried out by the investment management company (IMC).
Equities, subscription rights, exchange-traded funds (ETFs), participation certificates, bonds and exchange-traded derivatives are valued at their market price, provided that a market price is available.
Bonds for which no market price is available are valued at validated broker prices or with the help of regularly reviewed models and on the basis of relevant market information.
Participation certificates for which no market prices are available are valued at the mean of the bid-ask-spread.
Derivatives and subscription rights which are not traded on the market are valued with the help of regularly reviewed models and on the basis of relevant market information.
Investment fund units are valued at the redemption price published by the relevant investment company.
Bank deposits and other assets are valued at their nominal value, term deposits at their current value and liabilities at the repayment value.
Unlisted equities and shareholdings are valued at the current value, which is carefully determined with the help of suitable valuation models, taking account of the current market situation.
The methods used to value the Fund factor in the market effects resulting from the COVID-19 pandemic and from the Russia-Ukraine war. No further adjustments were necessary at the time of preparation of the semi-annual report.
The investments reported in this semi-annual report, amounting to 97.72% of fund assets, are valued at stock market trading prices or market prices and 0.00% at imputed current market values and/or verified brokers’ quotations. The remaining 2.28% of fund assets consists of other assets, other liabilities and cash.

#### Exchange rate(s) and/or conversion factor(s) (indirect quotation) as at 30/06/2022
USA, Dollar	(USD)	1 Euro = USD	1.04460

### Capital measures
All sales revenues resulting from capital measures (technical revenues) are reported as additions or disposals.

### Voting
To the extent it was deemed to be in our investors’ interest, we either exercised ourselves or had our agents exercise, in accordance with our instructions, voting rights for equities held by the Fund.

#### Transactions carried out during the reporting period no longer listed in the investment portfolio
– purchases and redemptions of securities, fund units and borrower’s note loans (market allocations as per reporting date):
ISIN	Securities	Shares/	Purchases	Redemptions Units/
Currency
Exchange-traded securities Equities
| Biotechnology |  |
| --- | --- |
| US04280A1007 | Arrowhead Pharmaceuticals Inc. Reg.Shares | Shs | 0 | 26,830 |
| CA05156V1022 | Aurinia Pharmaceuticals Inc. Reg.Shares | Shs | 0 | 11,965 |
| US10806X1028 | BridgeBio Pharma Inc. Reg.Shares | Shs | 0 | 33,228 |
| US15117B2025 | Celldex Therapeutics Inc. Reg.Shares | Shs | 0 | 30,305 |
| US29251M1062 | Enanta Pharmaceuticals Inc. Reg.Shares | Shs | 0 | 18,565 |
| US4277461020 | Heron Therapeutics Inc. Reg.Shares | Shs | 34,920 | 159,105 |
| US50015M1099 | Kodiak Sciences Inc. Reg.Shares | Shs | 0 | 16,175 |
| US53220K5048 | Ligand Pharmaceuticals Inc. Reg.Shares New | Shs | 5,875 | 5,875 |
| US5560991094 | MacroGenics Inc. Reg.Shares | Shs | 0 | 22,305 |
| US78667J1088 | Sage Therapeutics Inc. Reg.Shares | Shs | 16,420 | 16,430 |
| US80706P1030 | Scholar Rock Holding Corp. Reg.Shares | Shs | 0 | 45,835 |
| US8693671021 | Sutro Biopharma Inc. Reg.Shares | Shs | 0 | 37,089 |
| US88322Q1085 | TG Therapeutics Inc. Reg.Shares | Shs | 56,385 | 153,595 |
| US92764N1028 | Vir Biotechnology Inc. Reg.Shares | Shs | 0 | 26,100 |
| US98943L1070 | Zentalis Pharmaceuticals Inc. Reg.Shares | Shs | 0 | 26,345 |
| Biosciences: materials and services |
| US88025U1097 | 10X GENOMICS Inc. Reg.Shares | Shs | 3,430 | 15,770 |
| US05352A1007 | Avantor Inc. Reg.Shares | Shs | 0 | 97,745 |
| IE0005711209 | Icon PLC Reg.Shares | Shs | 0 | 11,330 |
| Retail: special |  |  |  |  |
| US71601V1052 | Petco Health+Wellness Co.Inc. Reg.Shares Cl.A | Shs | 0 | 42,555 |
| Electronic Devices, Instruments & Components |
| US65443P1021 | 908 Devices Inc. Reg.Shares | Shs | 0 | 40,900 |
| Healthcare: equipment and products |
| US08862L1035 | Beyond Air Inc. Reg.Shares | Shs | 197,347 | 197,347 |
| GB00BYMT0J19 | LivaNova PLC Reg.Shares | Shs | 11,015 | 11,015 |
| Healthcare: Institutions & Services |
| US40131M1099 | Guardant Health Inc. Reg.Shares Cl.A | Shs | 19,810 | 37,845 |
| Pharmaceuticals |  |  |  |  |
| US1488061029 | Catalent Inc. Reg.Shares | Shs | 0 | 32,995 |
| US3596161097 | Fulcrum Therapeutics Inc. Reg.Shares | Shs | 0 | 62,325 |
| US37733W1053 | GSK PLC Reg.Shares (Spons. ADRs) | Shs | 91,905 | 91,905 |
| US4131971040 | Harmony Biosciences Hldgs Inc. Reg.Shares | Shs | 34,835 | 34,835 |
| US6402681083 | Nektar Therapeutics Reg.Shares | Shs | 0 | 58,960 |
| US62921N1054 | NGM Biopharmaceuticals Inc. Reg.Shares | Shs | 41,070 | 41,070 |
| US6701002056 | Novo-Nordisk ASIndeh.Akt.B (Sp. ADRs) | Shs | 42,935 | 42,935 |

Unlisted securities (unlisted securities may also include listed securities due to their final maturity date)
Equities Biotechnology
US0400476075	Arena Pharmaceuticals Inc. Reg.Shares New	Shs	0	43,140
Derivatives Warrants
Securities	Shares/	Volume
Units/	in ’000
Currency
(Option premiums and/or contract volumes pertaining to opening transactions; in the case of warrants, purchases and redemptions are indicated.)
Wertpapier-Optionsscheine
Equity warrants
XF0009921218	Advanced Inhalation WTS (Foreign) 16/29.12.21	Shs	0	333,334

Translation (ENDE, 2022-06-30):
# Inhalt
Allianz Biotechnologie
Entwicklung von Fondsvermögen und Anteilwert im
Struktur des Fondsvermögens in %
|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  | 2,4  2,3 |

100
80
60
40
20
0
97,6 97,7
USD	Barreserve, Sonstiges
| Entwicklung von Fondsvermögen und Anteilwert im 3-Jahresvergleich |  |
| --- | --- |
|  | 30.06.2022 | 31.12.2021 | 31.12.2020 | 31.12.2019 |
| Fondsvermögen in Mio. EUR |  |  |  |  |
| - Anteilklasse A (EUR)	WKN: 848 186/ISIN: DE0008481862 | 273,3 | 305,7 | 267,9 | 296,0 |
| - Anteilklasse R (EUR)	WKN: A2A MPU/ISIN: DE000A2AMPU5 | 1,2 | 1,5 | 419.495,00  1) | 77.027,55  1) |
| Anteilwert in EUR |  |  |  |  |
| - Anteilklasse A (EUR)	WKN: 848 186/ISIN: DE0008481862 | 193,29 | 222,48 | 203,12 | 174,90 |
| - Anteilklasse R (EUR)	WKN: A2A MPU/ISIN: DE000A2AMPU5 | 142,05 | 162,79 | 147,35 | 125,76 |

1) 
Darstellungsweise nicht in Mio. EUR, aufgrund des geringen Fondsvermögens.
| Vermögensübersicht zum 30.06.2022 |  |
| --- | --- |
| Gliederung nach Anlagenart - Land | Kurswert in EUR | % des Fonds- vermögens  *) |  | Gliederung nach Anlagenart - Währung | Kurswert in EUR | % des Fonds- vermögens  *) |
| I. Vermögensgegenstände |  |  |  | I. Vermögensgegenstände |  |  |
| 1. Aktien | 268.253.099,61 | 97,72 |  | 1. Aktien | 268.253.099,61 | 97,72 |
| Deutschland | 2.795.834,39 | 1,02 |  | USD | 268.253.099,61 | 97,72 |
| Frankreich | 3.435.449,41 | 1,25 |  | 2. Bankguthaben, Geldmarktpapiere, | 5.946.676,58 | 2,16 |
| Niederlande | 6.923.425,61 | 2,52 |  | Geldmarkt- und geldmarktnahe Fonds |  |  |
| Irland | 13.100.537,00 | 4,77 |  | 3. Sonstige Vermögensgegenstände | 773.899,84 | 0,28 |

| Dänemark | 1.398.210,80 | 0,51 |
| --- | --- | --- |
| Schweiz | 1.808.199,69 | 0,66 |
| Großbritannien | 24.943.466,27 | 9,09 |
| USA | 208.542.113,72 | 75,96 |
| Kanada | 2.030.123,49 | 0,74 |
| Britische Jungfern-Inseln | 3.275.739,23 | 1,20 |
| 2. Bankguthaben, Geldmarktpapiere, Geldmarkt- und geldmarktnahe Fonds | 5.946.676,58 | 2,16 |
| 3. Sonstige Vermögensgegenstände | 773.899,84 | 0,28 |
| II. Verbindlichkeiten | -442.217,33 | -0,16 |
| III. Fondsvermögen | 274.531.458,70 | 100,00 |

*) 
Durch Rundung der Prozentanteile bei der Berechnung können geringfügige Run- dungsdifferenzen entstanden sein.
II. Verbindlichkeiten	-442.217,33	-0,16
III. Fondsvermögen	274.531.458,70	100,00

#### Vermögensaufstellung zum 30.06.2022
| ISIN | Gattungsbezeichnung | Markt | Stück bzw. | Bestand | Käufe/	Verkäufe/ | Kurs | Kurswert | % des |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  | Anteile bzw. | 30.06.2022 | Zugänge	Abgänge |  | in EUR | Fondsver- |
| Währung	im Berichtszeitraum	mögens Börsengehandelte Wertpapiere	268.253.099,61	97,72 |
| Aktien |  |  |  |  |  |  | 268.253.099,61 | 97,72 |
| Biotechnologie |  |  |  |  |  |  | 211.515.916,10 | 77,05 |
| US0042251084 | Acadia Pharmaceuticals Inc. Reg.Shares | STK | 48.205 | 18.805 | 0 USD | 14,220 | 656.208,21 | 0,24 |
| CH0499880968 | ADC Therapeutics S.A. Namens-Aktien Cl.C | STK | 61.760 | 12.330 | 0 USD | 7,790 | 460.569,02 | 0,17 |
| US0070021086 | Adicet Bio Inc. Reg.Shares | STK | 113.185 | 74.305 | 0 USD | 14,580 | 1.579.779,15 | 0,58 |
| US00847X1046 | Agios Pharmaceuticals Inc. Reg.Shares | STK | 62.105 | 19.605 | 0 USD | 22,380 | 1.330.566,63 | 0,48 |
| US0197701065 | Allogene Therapeutics Inc. Reg.Shares | STK | 45.285 | 0 | 0 USD | 11,680 | 506.345,78 | 0,18 |
| US02043Q1076 | Alnylam Pharmaceuticals Inc Reg.Shares | STK | 30.100 | 0 | 7.015 USD | 145,430 | 4.190.544,71 | 1,53 |
| US0231112063 | Amarin Corp. PLC Reg.Shs (Sp.ADRs) | STK | 8 | 0 | 0 USD | 1,820 | 13,94 | 0,00 |
| US0311621009 | Amgen Inc. Reg.Shares | STK | 99.210 | 38.895 | 27.250 USD | 245,430 | 23.309.506,32 | 8,50 |
| US03753U1060 | Apellis Pharmaceuticals Inc. Reg.Shares | STK | 46.640 | 34.810 | 0 USD | 45,190 | 2.017.673,37 | 0,73 |
| US04016X1019 | argenx SE Reg.Shares (Sp.ADRs) | STK | 18.670 | 8.175 | 3.835 USD | 373,580 | 6.676.946,77 | 2,43 |
| US04351P1012 | Ascendis Pharma A/S Nav.-Akt. (Spons.ADRs) | STK | 15.505 | 0 | 20.720 USD | 94,200 | 1.398.210,80 | 0,51 |
| US05153U1079 | Aura Biosciences Inc. Reg.Shares | STK | 61.575 | 6.430 | 0 USD | 12,570 | 740.951,32 | 0,27 |
| US07373V1052 | Beam Therapeutics Inc Reg.Shares | STK | 7.280 | 0 | 4.985 USD | 40,420 | 281.694,05 | 0,10 |
| US0887861088 | Bicycle Therapeutics Ltd. Reg.Shs (Spons.ADRs) | STK | 67.505 | 67.505 | 0 USD | 17,160 | 1.108.927,63 | 0,40 |
| US09058V1035 | BioCryst Pharmaceuticals Inc. Reg.Shares | STK | 297.865 | 175.525 | 36.065 USD | 10,810 | 3.082.443,66 | 1,12 |
| US09062X1037 | Biogen Inc. Reg.Shares | STK | 24.400 | 0 | 14.980 USD | 205,230 | 4.793.808,16 | 1,75 |
| VGG111961055 | Biohaven Pharmac.Hldg Co.Ltd. Reg.Shares | STK | 13.705 | 6.280 | 0 USD | 145,650 | 1.910.906,81 | 0,70 |
| US09061G1013 | Biomarin Pharmaceutical Inc. Reg.Shares | STK | 50.320 | 0 | 0 USD | 83,920 | 4.042.556,39 | 1,47 |
| US09075V1026 | BioNTech SE Nam.-Akt. (sp.ADRs) | STK | 20.570 | 16.050 | 23.990 USD | 141,980 | 2.795.834,39 | 1,02 |
| US09627Y1091 | Blueprint Medicines Corp. Reg.Shares | STK | 17.925 | 0 | 22.875 USD | 52,210 | 895.906,81 | 0,33 |
| US15678U1280 | Cerevel Therapeutics Hld. Inc. Reg.Shares | STK | 22.620 | 2.360 | 0 USD | 27,000 | 584.663,99 | 0,21 |
| US16383L1061 | ChemoCentryx Inc. Reg.Shares | STK | 72.225 | 19.800 | 0 USD | 25,490 | 1.762.411,69 | 0,64 |
| CH0334081137 | CRISPR Therapeutics AG Nam.-Aktien | STK | 22.345 | 0 | 10.130 USD | 63,000 | 1.347.630,67 | 0,49 |
| US23282W6057 | Cytokinetics Inc. Reg.Shares | STK | 89.910 | 90.850 | 68.235 USD | 48,740 | 4.195.111,43 | 1,53 |
| US23954D1090 | Day One Biopharmaceuticals Inc Reg.Shares | STK | 17.770 | 17.770 | 0 USD | 17,550 | 298.548,25 | 0,11 |
| US24823R1059 | Denali Therapeutics Inc. Reg.Shares | STK | 14.820 | 0 | 15.125 USD | 28,980 | 411.146,47 | 0,15 |
| US30161Q1040 | Exelixis Inc. Reg.Shares | STK | 30.420 | 52.625 | 22.205 USD | 20,790 | 605.429,64 | 0,22 |
| US31189P1021 | Fate Therapeutics Inc. Reg.Shares | STK | 15.825 | 0 | 21.065 USD | 24,880 | 376.915,57 | 0,14 |
| US3755581036 | Gilead Sciences Inc. Reg.Shares | STK | 316.835 | 16.520 | 56.415 USD | 62,480 | 18.950.651,73 | 6,90 |
| US40637H1095 | Halozyme Therapeutics Inc. Reg.Shares | STK | 34.935 | 0 | 0 USD | 45,280 | 1.514.318,21 | 0,55 |
| IE00BQPVQZ61 | Horizon Therapeutics PLC Reg.Shares | STK | 149.800 | 6.975 | 51.010 USD | 82,500 | 11.830.844,34 | 4,31 |
| US45253H1014 | ImmunoGen Inc. Reg.Shares | STK | 376.220 | 364.705 | 178.080 USD | 4,360 | 1.570.284,51 | 0,57 |
| US45337C1027 | Incyte Corp. Reg.Shares | STK | 30.635 | 0 | 18.270 USD | 75,890 | 2.225.627,18 | 0,81 |
| US4576693075 | Insmed Inc. Reg.Shares | STK | 186.020 | 99.085 | 0 USD | 20,070 | 3.574.020,10 | 1,30 |
| US45826J1051 | Intellia Therapeutics Inc. Reg.Shares | STK | 38.410 | 6.765 | 0 USD | 52,430 | 1.927.854,01 | 0,70 |
| US4622221004 | Ionis Pharmaceuticals Inc. Reg.Shares | STK | 9.830 | 0 | 58.200 USD | 37,560 | 353.450,89 | 0,13 |
| US4622601007 | Iovance Biotherapeutics Inc. Reg.Shares | STK | 79.880 | 35.680 | 0 USD | 10,890 | 832.752,44 | 0,30 |
| US46583P1021 | IVERIC Bio Inc. Reg.Shares | STK | 247.655 | 133.445 | 0 USD | 9,680 | 2.294.945,82 | 0,84 |
| US48576A1007 | Karuna Therapeutics Inc Reg.Shares | STK | 8.830 | 0 | 6.600 USD | 124,980 | 1.056.455,49 | 0,38 |
| US48576U1060 | Karyopharm Therapeutics Inc. Reg.Shares | STK | 145.925 | 15.240 | 20.280 USD | 4,510 | 630.022,74 | 0,23 |
| US4923271013 | Keros Therapeutics Inc. Reg.Shares | STK | 61.180 | 32.965 | 0 USD | 27,180 | 1.591.874,78 | 0,58 |
| US5011471027 | Krystal Biotech Inc. Reg.Shares | STK | 42.875 | 23.825 | 0 USD | 64,660 | 2.653.932,13 | 0,97 |
| US5015751044 | Kymera Therapeutics Inc. Reg.Shares | STK | 37.930 | 37.930 | 0 USD | 20,290 | 736.741,05 | 0,27 |
| US5588681057 | Madrigal Pharmaceuticals Inc. Reg.Shares | STK | 4.950 | 0 | 0 USD | 71,940 | 340.898,91 | 0,12 |
| US59045L1061 | Mersana Therapeutics Inc. Reg.Shares | STK | 191.525 | 20.005 | 0 USD | 4,450 | 815.897,23 | 0,30 |
| US60468T1051 | Mirati Therapeutics Inc. Reg.Shares | STK | 31.270 | 21.515 | 8.625 USD | 67,240 | 2.012.822,90 | 0,73 |
| US60770K1079 | Moderna Inc. Reg.Shares | STK | 117.250 | 76.055 | 38.530 USD | 142,810 | 16.029.554,37 | 5,84 |
| US61225M1027 | Monte Rosa Therapeutics Inc. Reg.Shares | STK | 82.145 | 82.145 | 0 USD | 9,790 | 769.863,63 | 0,28 |
| US61775R1059 | Morphic Holding Inc. Reg.Shares | STK | 48.625 | 31.370 | 0 USD | 21,170 | 985.440,60 | 0,36 |
| US6323071042 | Natera Inc. Reg.Shares | STK | 18.700 | 18.700 | 61.510 USD | 36,870 | 660.031,59 | 0,24 |
| US64125C1099 | Neurocrine Biosciences Inc. Reg.Shares | STK | 58.165 | 48.785 | 32.605 USD | 98,460 | 5.482.410,40 | 2,00 |
| US6700024010 | Novavax Inc. Reg.Shares | STK | 23.030 | 29.975 | 22.455 USD | 51,850 | 1.143.122,25 | 0,42 |
| US74349U1088 | Prometheus Biosciences Inc. Reg.Shares | STK | 51.533 | 40.463 | 0 USD | 27,820 | 1.372.437,35 | 0,50 |
| US74366E1029 | Protagonist Therapeutics Inc. Reg.Shares | STK | 123.120 | 75.100 | 19.825 USD | 8,070 | 951.156,81 | 0,35 |
| IE00B91XRN20 | Prothena Corp. PLC Reg.Shares | STK | 13.895 | 0 | 0 USD | 26,810 | 356.619,71 | 0,13 |
| US69366J2006 | PTC Therapeutics Inc. Reg.Shares | STK | 12.095 | 0 | 46.980 USD | 40,400 | 467.775,22 | 0,17 |
| US75886F1075 | Regeneron Pharmaceuticals Inc. Reg.Shares | STK | 19.950 | 2.220 | 820 USD | 597,620 | 11.413.477,89 | 4,16 |
| US77313F1066 | Rocket Pharmaceuticals Inc. Reg.Shares | STK | 20.470 | 0 | 0 USD | 13,030 | 255.336,11 | 0,09 |
| US8036071004 | Sarepta Therapeutics Inc. Reg.Shares | STK | 6.015 | 0 | 0 USD | 77,070 | 443.783,31 | 0,16 |
| US81181C1045 | Seagen Inc. Reg.Shares | STK | 55.400 | 11.395 | 18.500 USD | 179,060 | 9.496.385,22 | 3,46 |
| US85205L1070 | SpringWorks Therapeutics Inc. Reg.Shares | STK | 94.425 | 81.065 | 0 USD | 25,500 | 2.305.033,03 | 0,84 |
| US87164F1057 | Syndax Pharmaceuticals Inc. Reg.Shares | STK | 87.555 | 26.125 | 0 USD | 19,080 | 1.599.224,01 | 0,58 |
| US89422G1076 | Travere Therapeutics Inc. Reg.Shares | STK | 89.525 | 38.605 | 0 USD | 24,680 | 2.115.141,68 | 0,77 |

Die Fußnotenerklärungen befinden sich am Ende der Tabelle.

#### Vermögensaufstellung zum 30.06.2022
| ISIN | Gattungsbezeichnung	Markt | Stück bzw. Anteile bzw. Währung | Bestand 30.06.2022 | Käufe/	Verkäufe/ Zugänge	Abgänge im Berichtszeitraum | Kurs | Kurswert in EUR | % des Fondsver- mögens |
| --- | --- | --- | --- | --- | --- | --- | --- |
| US90041T1088 | Turning Point Therap. Inc. Reg.Shares | STK | 13.820 | 0 | 1.603 USD | 75,300 | 996.214,82 | 0,36 |
| US90400D1081 | Ultragenyx Pharmaceutical Inc. Reg.Shares | STK | 21.095 | 10.730 | 8.565 USD | 60,240 | 1.216.506,61 | 0,44 |
| NL0010696654 | uniQure N.V. Aandelen op naam | STK | 13.940 | 13.940 | 0 USD | 18,470 | 246.478,84 | 0,09 |
| US91307C1027 | United Therapeutics Corp.(Del.) Reg.Shares | STK | 18.975 | 7.345 | 12.250 USD | 238,290 | 4.328.501,58 | 1,58 |
| US92532F1003 | Vertex Pharmaceuticals Inc. Reg.Shares | STK | 75.000 | 12.895 | 6.585 USD | 280,350 | 20.128.518,09 | 7,34 |
| CA98420N1050 | Xenon Pharmaceuticals Inc. Reg.Shares | STK | 68.630 | 29.145 | 20.720 USD | 30,900 | 2.030.123,49 | 0,74 |
| US9842411095 | Y-Mabs Therapeutics Inc. Reg.Shares | STK | 32.085 | 3.350 | 0 USD | 14,590 | 448.133,40 | 0,16 |
| Biowissenschaften Hilfsmittel & Dienstleistungen	7.229.686,73	2,64 |
| US23285D1090 | Cytek Biosciences Inc. Reg.Shares | STK | 30.415 | 30.415 | 0 USD | 10,870 | 316.495,36 | 0,12 |
| US4523271090 | Illumina Inc. Reg.Shares | STK | 15.395 | 10.665 | 25.980 USD | 186,430 | 2.747.549,16 | 1,00 |
| US46266C1053 | IQVIA Holdings Inc. Reg.Shares | STK | 8.600 | 8.600 | 0 USD | 214,110 | 1.762.728,32 | 0,64 |
| US56600D1072 | Maravai LifeSciences Hldgs Inc Reg.Shares Cl.A | STK | 40.155 | 40.155 | 20.375 USD | 27,810 | 1.069.031,73 | 0,39 |
| US58506Q1094 | Medpace Holdings Inc. Reg.Shares | STK | 2.060 | 0 | 16.045 USD | 149,980 | 295.767,57 | 0,11 |
| US87166B1026 | Syneos Health Inc. Reg.Shares A | STK | 15.030 | 23.850 | 58.885 USD | 72,150 | 1.038.114,59 | 0,38 |
| Gesundheitswesen: Ausstattung & Produkte	12.415.136,90	4,51 |
| US05465P1012 | Axonics Inc. Reg.Shares | STK | 15.325 | 61.385 | 46.060 USD | 57,680 | 846.205,25 | 0,31 |
| US2521311074 | DexCom Inc. Reg.Shares | STK | 27.860 | 27.860 | 0 USD | 75,450 | 2.012.288,91 | 0,73 |
| VGG312491084 | Establishment Labs Holdings In Reg.Shares | STK | 25.265 | 13.485 | 12.265 USD | 56,430 | 1.364.832,42 | 0,50 |
| US45168D1046 | IDEXX Laboratories Inc. Reg.Shares | STK | 2.110 | 2.110 | 1.685 USD | 358,220 | 723.572,85 | 0,26 |
| JE00BYSS4X48 | Novocure Ltd. Reg.Shares | STK | 40.500 | 14.880 | 9.520 USD | 72,400 | 2.807.007,47 | 1,02 |
| US70975L1070 | Penumbra Inc. Reg.Shares | STK | 5.450 | 5.450 | 0 USD | 130,250 | 679.554,37 | 0,25 |
| JE00BLG2ZQ72 | Quotient Ltd. Reg.Shares | STK | 113.495 | 0 | 0 USD | 0,248 | 26.890,69 | 0,01 |
| US82489T1043 | Shockwave Medical Inc. Reg.Shares | STK | 7.150 | 7.150 | 0 USD | 194,370 | 1.330.409,25 | 0,48 |
| US82710M1009 | Silk Road Medical Inc. Reg.Shares | STK | 30.145 | 30.145 | 0 USD | 37,500 | 1.082.172,60 | 0,39 |
| US8753722037 | Tandem Diabetes Care Inc. Reg.Shares New | STK | 26.765 | 38.460 | 11.695 USD | 60,190 | 1.542.203,09 | 0,56 |
| Gesundheitswesen: Technologie	810.772,45	0,30 |
| US4577301090 | Inspire Medical Systems Inc. Reg.Shares | STK | 4.510 | 4.510 | 0 USD | 187,790 | 810.772,45 | 0,30 |
| Pharmazeutika |  |  |  |  |  |  | 36.281.587,43 | 13,22 |
| US00461U1051 | Aclaris Therapeutics Inc. Reg.Shares | STK | 83.930 | 33.890 | 0 USD | 14,360 | 1.153.776,37 | 0,42 |
| US00771V1089 | Aerie Pharmaceuticals Inc. Reg.Shares | STK | 145.275 | 36.450 | 0 USD | 7,800 | 1.084.764,50 | 0,40 |
| US04335A1051 | Arvinas Inc. Reg.Shares | STK | 43.630 | 18.070 | 0 USD | 43,640 | 1.822.719,89 | 0,66 |
| US0463531089 | Astrazeneca PLC Reg.Shares (Spons.ADRs)	STK | 327.324 | 96.775 | 65.595 USD | 67,020 | 21.000.626,54 | 7,66 |
| US05464T1043 | Axsome Therapeutics Inc. Reg.Shares | STK | 5.960 | 5.960 | 0 USD | 36,490 | 208.194,91 | 0,08 |
| US46116X1019 | Intra-Cellular Therapies Inc. Reg.Shares | STK | 12.450 | 0 | 0 USD | 58,310 | 694.964,10 | 0,25 |
| IE00B4Q5ZN47 | Jazz Pharmaceuticals PLC Reg.Shares | STK | 6.100 | 6.100 | 0 USD | 156,360 | 913.072,95 | 0,33 |
| US7170811035 | Pfizer Inc. Reg.Shares | STK | 55.775 | 170.735 | 178.185 USD | 50,940 | 2.719.872,20 | 0,99 |
| US75615P1030 | Reata Pharmaceuticals Inc. Reg.Shares | STK | 9.030 | 0 | 0 USD | 32,050 | 277.054,85 | 0,10 |
| US80105N1054 | Sanofi S.A. Act.Nom. (Sp. ADRs) | STK | 68.135 | 68.135 | 0 USD | 52,670 | 3.435.449,41 | 1,25 |
| US98978V1035 | Zoetis Inc. Reg.Shares Cl.A | STK | 17.845 | 17.845 | 0 USD | 173,920 | 2.971.091,71 | 1,08 |
| Nichtnotierte Wertpapiere |  |  |  |  |  | 0,00 | 0,00 |
| Andere Wertpapiere |  |  |  |  |  | 0,00 | 0,00 |
| US284CVR0169	Elanco Animal Health Inc. An- |  |  |  |  |  |  |  |
| rechte (CVR Rights) | STK | 64.110 | 0 | 0 USD | 0,000 | 0,00 | 0,00 |
| Summe Wertpapiervermögen |  |  |  | EUR |  | 268.253.099,61 | 97,72 |
| Bankguthaben, Geldmarktpapiere, Geldmarkt- und geldmarktnahe Fonds |  |  |  |  |  |  |  |
| Bankguthaben |  |  |  |  |  |  |  |
| EUR-Guthaben bei der Verwahrstelle |  |  |  |  |  |  |  |
| State Street Bank International GmbH | EUR | 5.775.570,94 |  | % | 100,000 | 5.775.570,94 | 2,10 |
| Guthaben in Nicht-EU/EWR-Währungen |
| State Street Bank International GmbH | USD | 178.736,95 | % | 100,000 | 171.105,64 | 0,06 |

| Summe Bankguthaben |  | EUR | 5.946.676,58 | 2,16 |
| --- | --- | --- | --- | --- |
| Summe der Bankguthaben, Geldmarktpapiere, Geldmarkt- und geldmarktnahe Fonds  30) |  | EUR | 5.946.676,58 | 2,16 |
| Sonstige Vermögensgegenstände |  |  |  |  |
| Dividendenansprüche	EUR | 51.421,05 |  | 51.421,05 | 0,02 |
| Forderungen aus Anteilscheingeschäften	EUR | 90.429,80 |  | 90.429,80 | 0,03 |
| Forderungen aus Wertpapiergeschäften	EUR | 632.048,99 |  | 632.048,99 | 0,23 |
| Summe Sonstige Vermögensgegenstände |  | EUR | 773.899,84 | 0,28 |
| Sonstige Verbindlichkeiten |  |  |  |  |
| Verbindlichkeiten aus Anteilscheingeschäften	EUR | -5.635,98 |  | -5.635,98 | 0,00 |
| Kostenabgrenzung	EUR | -436.581,35 |  | -436.581,35 | -0,16 |
| Summe Sonstige Verbindlichkeiten |  | EUR | -442.217,33 | -0,16 |
| Fondsvermögen |  | EUR | 274.531.458,70 | 100,00 |
| Summe der umlaufenden Anteile aller Anteilklassen |  | STK | 1.422.535 |  |

30) 
Im Bankguthaben können Cash Initial Margin enthalten sein.
Allianz Biotechnologie A (EUR)
| ISIN | DE0008481862 |
| --- | --- |
| Fondsvermögen | 273.319.155,72 |
| Umlaufende Anteile | 1.414.000,732 |
| Anteilwert | 193,29 |

Allianz Biotechnologie R (EUR)
| ISIN | DE000A2AMPU5 |
| --- | --- |
| Fondsvermögen | 1.212.302,98 |
| Umlaufende Anteile | 8.534,382 |
| Anteilwert | 142,05 |


### Wertpapierkurse bzw. Marktsätze
Die Vermögensgegenstände des Sondervermögens sind auf der Grundlage nachstehender Kurse/Marktsätze bewertet:
Aktien Nord- und Südamerika: Kurse per 29.06.2022 oder letztbekannte
Alle anderen Vermögenswerte: Kurse bzw. Marktsätze per 30.06.2022 oder letztbekannte

### Ergänzende Anmerkung zur Bewertung
Die Bewertung erfolgt durch die Kapitalverwaltungsgesellschaft (KVG).
Aktien, Bezugsrechte, Börsennotierte Fonds (ETFs), Genussscheine, Rentenpapiere und börsengehandelte Derivate werden, sofern vorhanden, grundsätz- lich mit handelbaren Börsenkursen bewertet.
Rentenpapiere, für die keine handelbaren Börsenkurse vorliegen, werden mit validierten Kursstellungen von Brokern oder unter Einbeziehung der relevan- ten Marktinformationen im Rahmen von regelmäßig überprüften Modellen bewertet.
Genussscheine, für die keine handelbaren Börsenkurse vorliegen, werden mit dem Mittelwert von Bid- und Ask-Kurs bewertet.
Nicht börsengehandelte Derivate und Bezugsrechte werden unter Einbeziehung der relevanten Marktinformationen im Rahmen von regelmäßig über- prüften Modellen bewertet.
Investmentfondsanteile werden mit dem von der Investmentgesellschaft veröffentlichten Rücknahmepreis bewertet.
Bankguthaben und Sonstige Vermögensgegenstände werden zum Nennwert, Festgelder zum Verkehrswert und Verbindlichkeiten zum Rückzahlungsbe- trag bewertet.
Nicht notierte Aktien und Beteiligungen werden zu dem aktuellen Verkehrswert bewertet, der bei sorgfältiger Einschätzung nach geeigneten Bewertungs- modellen unter Berücksichtigung der aktuellen Marktgegebenheiten angemessen ist.
Die angewandten Verfahren zur Bewertung des Sondervermögens decken die aus der Covid-Pandemie und aus dem Russland-Ukraine-Krieg herrühren- den Marktauswirkungen ab. Darüber hinausgehende Anpassungen waren zum Zeitpunkt der Aufstellung des Halbjahresberichts nicht erforderlich.
Die in diesem Halbjahresbericht ausgewiesenen Anlagen werden i.H.v. 97,72% des Fondsvermögens mit handelbaren Börsenkursen oder Marktpreisen und 0,00% zu abgeleiteten Verkehrswerten bzw. validierten Kursstellungen von Brokern bewertet. Die verbleibenden 2,28% des Fondsvermögens bestehen aus Sonstigen Vermögensgegenständen, Sonstigen Verbindlichkeiten sowie Barvermögen.

#### Devisenkurs(e) bzw. Konversionsfaktor(en) (in Mengennotiz) per 30.06.2022
USA, Dollar	(USD)	1 Euro = USD	1,04460

### Kapitalmaßnahmen
Alle Umsätze, die aus Kapitalmaßnahmen hervorgehen (technische Umsätze), werden als Zu- oder Abgang ausgewiesen.

### Stimmrechtsausübung
Stimmrechte aus den im Fonds enthaltenen Aktien haben wir, soweit es im Interesse unserer Anleger geboten erschien, entweder selbst wahrgenommen oder durch Beauftragte nach unseren Weisungen ausüben lassen.

#### Während des Berichtszeitraumes abgeschlossene Geschäfte, soweit sie nicht mehr in der Vermögensaufstellung erscheinen
- Käufe und Verkäufe in Wertpapieren, Investmentanteilen und Schuldscheindarlehen (Marktzuordnung zum Berichtsstichtag):
| ISIN | Gattungsbezeichnung | Stück bzw. | Käufe/ | Verkäufe/ |
| --- | --- | --- | --- | --- |
|  |  | Anteile bzw. Währung | Zugänge | Abgänge |

Börsengehandelte Wertpapiere Aktien
Biotechnologie
| US04280A1007 | Arrowhead Pharmaceuticals Inc. Reg.Shares | STK | 0 | 26.830 |
| --- | --- | --- | --- | --- |
| CA05156V1022 | Aurinia Pharmaceuticals Inc. Reg.Shares | STK | 0 | 11.965 |
| US10806X1028 | BridgeBio Pharma Inc. Reg.Shares | STK | 0 | 33.228 |
| US15117B2025 | Celldex Therapeutics Inc. Reg.Shares | STK | 0 | 30.305 |
| US29251M1062 | Enanta Pharmaceuticals Inc. Reg.Shares | STK | 0 | 18.565 |
| US4277461020 | Heron Therapeutics Inc. Reg.Shares | STK | 34.920 | 159.105 |
| US50015M1099 | Kodiak Sciences Inc. Reg.Shares | STK | 0 | 16.175 |
| US53220K5048 | Ligand Pharmaceuticals Inc. Reg.Shares New | STK | 5.875 | 5.875 |
| US5560991094 | MacroGenics Inc. Reg.Shares | STK | 0 | 22.305 |
| US78667J1088 | Sage Therapeutics Inc. Reg.Shares | STK | 16.420 | 16.430 |
| US80706P1030 | Scholar Rock Holding Corp. Reg.Shares | STK | 0 | 45.835 |
| US8693671021 | Sutro Biopharma Inc. Reg.Shares | STK | 0 | 37.089 |
| US88322Q1085 | TG Therapeutics Inc. Reg.Shares | STK | 56.385 | 153.595 |
| US92764N1028 | Vir Biotechnology Inc. Reg.Shares | STK | 0 | 26.100 |
| US98943L1070 | Zentalis Pharmaceuticals Inc. Reg.Shares | STK | 0 | 26.345 |
| Biowissenschaften Hilfsmittel & Dienstleistungen |
| US88025U1097 | 10X GENOMICS Inc. Reg.Shares | STK | 3.430 | 15.770 |
| US05352A1007 | Avantor Inc. Reg.Shares | STK | 0 | 97.745 |
| IE0005711209 | Icon PLC Reg.Shares | STK | 0 | 11.330 |
| Einzelhandel: Spezial |
| US71601V1052 | Petco Health+Wellness Co.Inc. Reg.Shares Cl.A | STK | 0 | 42.555 |
| Elektronische Geräte, Instrumente & Komponenten |
| US65443P1021 | 908 Devices Inc. Reg.Shares | STK | 0 | 40.900 |
| Gesundheitswesen: Ausstattung & Produkte |
| US08862L1035 | Beyond Air Inc. Reg.Shares | STK | 197.347 | 197.347 |
| GB00BYMT0J19 | LivaNova PLC Reg.Shares | STK | 11.015 | 11.015 |
| Gesundheitswesen: Einrichtungen & Dienste |
| US40131M1099 | Guardant Health Inc. Reg.Shares Cl.A | STK | 19.810 | 37.845 |
| Pharmazeutika |  |  |  |  |
| US1488061029 | Catalent Inc. Reg.Shares | STK | 0 | 32.995 |
| US3596161097 | Fulcrum Therapeutics Inc. Reg.Shares | STK | 0 | 62.325 |
| US37733W1053 | GSK PLC Reg.Shares (Spons. ADRs) | STK | 91.905 | 91.905 |
| US4131971040 | Harmony Biosciences Hldgs Inc. Reg.Shares | STK | 34.835 | 34.835 |
| US6402681083 | Nektar Therapeutics Reg.Shares | STK | 0 | 58.960 |
| US62921N1054 | NGM Biopharmaceuticals Inc. Reg.Shares | STK | 41.070 | 41.070 |
| US6701002056 | Novo-Nordisk ASIndeh.Akt.B (Sp. ADRs) | STK | 42.935 | 42.935 |

Nichtnotierte Wertpapiere (Unter den nicht notierten Wertpapieren können auch notierte Wertpapiere aufgrund ihrer Endfälligkeit ausgewiesen sein) Aktien
Biotechnologie
US0400476075	Arena Pharmaceuticals Inc. Reg.Shares New	STK	0	43.140
Derivate Optionsscheine
Gattungsbezeichnung	Stück bzw.	Volumen
Anteile bzw.	in 1.000
Währung
(In Opening-Transaktionen umgesetzte Optionsprämien bzw. Volumen der Optionsgeschäfte, bei Optionsscheinen Angabe der Käufe und Verkäufe.)
Wertpapier-Optionsscheine
Optionsscheine auf Aktien
XF0009921218	Advanced Inhalation WTS (Foreign) 16/29.12.21	STK	0	333.334